氨苯砜和氯法齐明抗分枝杆菌体外活性  

Activities of dapsone and clofazimine against mycobacteria in vitro

作　　者：冯雨苗[1] 王洪生[1] 胡忠义 王洁 张彩萍[1] 王淼淼[1] 林麟[1] 吴勤学[1] 

机构地区：[1]中国医学科学院皮肤病研究所,南京210042 [2]上海市结核病重点实验室,上海200433

出　　处：《中国麻风皮肤病杂志》2009年第11期806-808,共3页China Journal of Leprosy and Skin Diseases

基　　金：中央级公益性科研院所基本科研业务专项;江苏省自然基金(项目编号:BK2006015);江苏省卫生厅基金(项目编号:H200638)

摘　　要：目的:评价常见分枝杆菌对氨苯砜和氯法齐明的体外敏感性。方法:根据美国临床和实验室标准协会(CLSI)M24-A液基微量稀释法测定结核杆菌、海鱼、堪萨斯、田鼠、新金色、土、偶发、龟、脓肿和耻垢分枝杆菌标准株对氨苯砜和氯法齐明的体外MIC值。结果:结核、海鱼和堪萨斯分枝杆菌对氯法齐明敏感,所有菌株对氨苯砜耐药。结论:氯法齐明是一种治疗结核、海鱼和堪萨斯分枝杆菌感染有潜力的药物。Objective： To evaluate the susceptibility of clinical common mycobacteria to clofazimine and dapsone in vitro. Methods： Clinical Laboratory Standard Institute （CLSI） broth microdilution method M24- A was applied to test the susceptibility of mycobacterial control strains to dapsone and clofazimine, including M. tuberculosis, M. marinum, M. kansasii, M. microti, M. neoaurum, M. terrae, M. fortuitum, M. chelonae, M. abscessus and M. smegmatis. Results： Of all strains, only M. tuberculosis, M. marinum and M. kanscssii were sensitive to clofazimine. All strains were resistant to dapsone. Conclusion： Clofazimine appears to be a potential agent against M. tuberculosis, M. magnum and M. kansasii.

关 键 词：分枝杆菌 CLSI M24-A 敏感性试验 氨苯砜 氯法齐明 

分 类 号：R96[医药卫生—药理学]